Skip to content
TrialScanner

NCT06079190

Efficacy and Safety of GSK4527226 [AL101] in Participants With Early Alzheimer's Disease

Phase 2TerminatedGSKLeadALECCollaborator

Registry record

Lead sponsor
GlaxoSmithKline
Conditions
Alzheimer's Disease
Primary completion
May 14, 2026Actual
Completion
Locked
Start
Locked
Enrollment
Locked
Interventions
Locked
Study type
Locked
Results on the registry
Locked
Record last updated
Locked

Open NCT06079190 on ClinicalTrials.gov

Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.

Unlock with TrialScanner

Recorded changes

0 changes recorded for this trial. The history, with each previous value, is part of TrialScanner.

Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.

    NCT06079190: Efficacy and Safety of... | TrialScanner